Nunn, AD. Molecular imaging and personalized medicine: An uncertain future. Cancer Biother Radiopharm. 2007;22:722–739. PubMed PMID: 18158763.
Hillman, BJ, Goldsmith, JC. The uncritical use of high-tech medical imaging. N Engl J Med. 2010;363:4–6. PubMed PMID: ISI:000279343000002.
Government Accountability Office. GAO 08–452, Medicare Part B Imaging Services. Rapid spending growth and shift to physician offices indicate need for CMS to consider additional management practices 2008. http://www.gao.gov/highlights/d08452high.pdf (accessed April 3, 2012).
Winter, A, Ray, N. Paying accurately for imaging services in Medicare. Health Aff (Millwood). 2008;27:1479–1490.
Levin, DC, Rao, VM, Parker, L, Frangos, AJ, Sunshine, JH. Bending the curve: The recent marked slowdown in growth of noninvasive diagnostic imaging. AJR Am J Roentgenol. 2011;196:W25–W29. PubMed PMID: 21178027.
Caire, AA, Sun, L, Ode, O, et al.
Delayed prostate-specific antigen recurrence after radical prostatectomy: How to identify and what are their clinical outcomes? Urology. 2009;74:643–7. PubMed PMID: 19501891.
Stephenson, AJ, Shariat, SF, Zelefsky, MJ, et al.
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325–1332. PubMed PMID: 15026399.
Bensink, M, Wyatt, K, Musa, Z, et al.
Using economic evaluation to guide technology development decisions in nuclear medicine: Functional imaging for identifying non-response to bevacizumab in patients with advanced colorectal cancer. J Nucl Med. 2013. In press.
Sculpher, M, Drummond, M, Buxton, M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy. 1997;2:26–30.
Warburton, R. Patient saftey-how much is enough?
Health Policy. 2005;75:223–232.
Vallejo-Torres, L, Steuten, LM, Buxton, MJ, et al.
Integrating health economics modeling in the product development cycle of medical devices: A Bayesian approach. Int J technol assess health care. 2008;24:459–464. PubMed PMID: 18828941.
Schuster, DM, Nieh, PT, Jani, AB, et al.
Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: Results of a prospective clinical trial. J Urol. 2014;191:1446–1453.
Husereau, D, Drummond, M, Petrou, S, et al.
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care. 2013;29:117–122.
Stewart, ST, Lenert, L, Bhatnagar, V, Kaplan, RM. Utilities for prostate cancer health states in men aged 60 and older. Med Care. 2005;43:347–355. PubMed PMID: 15778638.
Trock, BJ, Han, M, Freedland, SJ, et al.
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299:2760–2769. PubMed PMID: 18560003. Pubmed Central PMCID: NIHMS283299.
Lu-Yao, G, Moore, DF, Oleynick, JU, DiPaola, RS, Yao, S-L. Population based study of hormonal therapy and survival in men with metastatic prostate cancer. J Urol. 2007;177:535–539. PubMed PMID: 17222628.
Penson, DF, Moul, JW, Evans, CP, et al.
The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: Findings from a retrospective analysis of health plan data. J Urol. 2004;171
(Pt 1):2250–2254. PubMed PMID: 15126796.
Schuster, DM, Savir-Baruch, B, Nieh, PT, et al.
Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology. 2011;259:852–861.
Stephenson, AJ, Scardino, PT, Kattan, MW, et al.
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035–2041.
Nanni, C, Schiavina, R, Boschi, S, et al.
Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: Preliminary results. Eur J Nucl Med Mol Imaging. 2013;40:11–17.
Beresford, MJ, Gillatt, D, Benson, RJ, Ajithkumar, T. A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol (R Coll Radiol). 2010;22:46–55. PubMed PMID: 19948393.
Giovacchini, G, Picchio, M, Briganti, A, et al.
[11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol. 2010;184:938–943. PubMed PMID: 20643445.
Okotie, OT, Aronson, WJ, Wieder, JA, et al.
Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol. 2004;171
(Pt 1):2260–2264. PubMed PMID: 15126798.
Arias, E. United States life tables, 2007. Natl Vital Stat Rep. 2011;59:1–60. PubMed PMID: 22070012.
US Department of labor. Consumer price index medical (CPI-M) January 1947 to July 2012. Washington, DC: Bureau of labor statistics, US Department of labor; 2012.
Murphy, M. Proximity to death and health care costs. In: McGuire, A, Costa-Font, J, eds. The LSE companion to health policy. Northampton, MA: Edwards Elgar Publishing; 2012:221–232.
Morrison, RS, Penrod, JD, Cassel, JB, et al.
Cost savings associated with US hospital palliative care consultation programs. Arch Intern Med. 2008;168:1783–90. PubMed PMID: 18779466.
Tefilli, MV, Gheiler, EL, Tiguert, R, et al.
Quality of life in patients undergoing salvage procedures for locally recurrent prostate cancer. J Surg Oncol.
1998;69:156–161. PubMed PMID: 9846502.
Sanda, MG, Dunn, RL, Michalski, J, et al.
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008 20;358:1250–1261. PubMed PMID: 18354103.
Kyrdalen, AE, Dahl, AA, Hernes, E, Småstuen, MC, Fosså, SD. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int. 2013;111:221–232.
Potosky, AL, Davis, WW, Hoffman, RM, et al.
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The prostate cancer outcomes study. J Natl Cancer Inst. 2004;96:1358–67. PubMed PMID: 15367568.
Lentzner, HR, Pamuk, ER, Rhodenhiser, EP, Rothenberg, R, Powell-Griner, E. The quality of life in the year before death. Am J Public Health. 1992;82:1093–1098. PubMed PMID: 1386195.
Liao, Y, McGee, DL, Cao, G, Cooper, RS. Quality of the last year of life of older adults: 1986 vs 1993. JAMA. 2000;283:512–518. PubMed PMID: 10659878.
Benjamins, MR, Hummer, RA, Eberstein, IW, Nam, CB. Self-reported health and adult mortality risk: An analysis of cause-specific mortality. Soc Sci Med. 2004;59:1297–1306. PubMed PMID: 15210100.
DeSalvo, KB, Fan, VS, McDonell, MB, Fihn, SD. Predicting mortality and healthcare utilization with a single question. Health Serv Res. 2005;40:1234–1246. PubMed PMID: 16033502.
Myint, PK, Luben, RN, Surtees, PG, et al.
Relation between self-reported physical functional health and chronic disease mortality in men and women in the European Prospective Investigation into Cancer (EPIC-Norfolk): A prospective population study. Ann Epidemiol. 2006;16:492–500. PubMed PMID: 16005244.
Grosse, SD. Assessing cost-effectiveness in healthcare: History of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8:165–178. PubMed PMID: 20528406.
Torgerson, DJ, Raftery, J. Economic notes. Discounting. BMJ.
1999;319:914–915. PubMed PMID: 10506056.